Abstract
Introduction
Myasthenia gravis is a long-lasting autoimmune neuromuscular disease caused by antibodies attacking the neuromuscular junction, which can result in muscle weakness, fatigue, and respiratory failure in severe cases. Myasthenic crisis is a life-threatening event that requires hospitalization and treatments with intravenous immunoglobulin or plasma exchange. We reported the case of an AChR-Ab-positive myasthenia gravis patient with refractory myasthenic crisis, in which starting eculizumab as rescue therapy led to a complete resolution of the acute neuromuscular condition.
Case presentation
A 74-year-old man diagnosed with myasthenia gravis. ACh-receptor antibodies positivity comes to our observation for a recrudescence of symptoms, unresponsive to conventional rescue therapies. Due to the clinical worsening over the following weeks, the patient was admitted to intensive care unit, where he underwent therapy with eculizumab. About 5 days after the treatment, there was a significant and complete recovery of clinical condition with weaning-off from invasive ventilation and discharge to outpatient regimen, with reduction of steroid intake and biweekly maintenance with eculizumab.
Discussion
Eculizumab, a humanized monoclonal antibody that inhibits complement activation, is now approved as treatment for refractory generalized myasthenia gravis with anti-AChR antibodies. The use of eculizumab in myasthenic crisis is still investigational, but this case report suggests that it may be a promising treatment option for patients with severe clinical condition. Ongoing clinical trials will be needed to further evaluate the safety and efficacy of eculizumab in myasthenic crisis.
Data availability
All data generated or analyzed during this study are included in this published article.
References
Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJGM (2019) Myasthenia gravis. Nat Rev Dis Primers 5:30
Vanoli F, Mantegazza R (2022) Antibody therapies in autoimmune neuromuscular junction disorders: approach to myasthenic crisis and chronic management. Neurotherapeutics 19:897–910
Roper J, Fleming ME, Long B, Koyfman A (2017) Myasthenia gravis and crisis: evaluation and management in the emergency department. J Emerg Med 53:843–853
Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O'Brien F, Wang JJ, Mantegazza R, REGAIN Study Group (2017) Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 16:976–986
Monteleone J, Gao X, Kleijn HJ et al (2021) Eculizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis. Front Neurol 12:696385. https://doi.org/10.3389/fneur.2021.696385 eCollection 2021
Patriquin CJ (2019) Kuo KHM Eculizumab and beyond: the past, present, and future of complement therapeutics. Transfus Med Rev 33(4):256–265
Yeo CJJ, Pleitez MY (2018) Eculizumab in refractory myasthenic crisis. Muscle Nerve 58:E13–E15
Usman U, Chrisman C, Houston D et al (2021) The use of eculizumab in ventilator-dependent myasthenia gravis patients. Muscle Nerve 64(2):212–215. https://doi.org/10.1002/mus.27326
Hofstadt-van Oy U, Stankovic S, Kelbel C, Oswald D, Larrosa-Lombardi S, Barchfeld T, Cleff U (2021) Complement inhibition initiated recovery of a severe myasthenic crisis with COVID-19. J Neurol 268:3125–3128
Strano CMM, Sorrenti B, Bosco L, Falzone YM, Fazio R, Filippi M (2022) Eculizumab as a fast-acting rescue therapy in a refractory myasthenic crisis: a case report. J Neurol 269:6152–6154
Author information
Authors and Affiliations
Contributions
C. Vinciguerra received compensation for speaking activities from Alexion. P. Barone received compensation for consulting services from Alexion, Roche, Zambon, UCB, Bial, AbbVie Pharmaceutical Industries. L. Bevilacqua, A. Toriello, G. Piscosquito, A. Iovino, and G. Calicchio, report no disclosures.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no competing interests
Ethical approval
Written informed consent was obtained from the patient for publication of anonymized data. We confirm that we have read the journal’s position on issues involved in ethical publication and affirm that this work is consistent with those guidelines.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Vinciguerra, C., Bevilacqua, L., Toriello, A. et al. Starting eculizumab as rescue therapy in refractory myasthenic crisis. Neurol Sci 44, 3707–3709 (2023). https://doi.org/10.1007/s10072-023-06900-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-023-06900-y